I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 02307K-085040US

Client reference No.: 93-239-2

OIPE

FEB 1 5 2001

PRADEMAR PRADEMAR

Assistant Commissioner for Patents
Washington, D.C. 20231

# 15

Labourance

TOWNSEND and TOWNSEND and CREW LLP

By:\_\_\_\_\_\_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Charo, Israel F.

Application No.: 09/625,573

Filed: July 25, 2000

For: MAMMALIAN MONOCYTE CHEMOATTRACTANT PROTEIN

RECEPTORS

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the reference items AA, AB, AC, AT and BC are enclosed pursuant to 37 CFR 1.98 (a)(2). Copies of the remaining disclosures are not being provided pursuant to 37 CFR 1.98 (d), as the cited references have been previously sited by or submitted to the Patent Office in prior application 08/446,669 filed May 25, 1995, to which the above identified application claims priority. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the

Charo, Israel F.

Application No.: 09/625,573

Page 2

references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the abovenoted Deposit Account.

Respectfully submitted,

Andrew T. Serafini Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 415 576-0200

Fax: 650 326-2422

PA 3117581 v1

		TPA				00//05 572							
FORM PTO-1449 (Modified)  LIST OF PATENTS AND PURLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Attorney Docket No.: 02307K-085040US Application No.: 09/625,573  Applicant: Israel F. Charo  Filing Date: July 25, 2000 Croup: Unassigned										
								Use several speed	PRADENIARIE	U.S. PATENT DOCUMEN	NTS FEB 15	2001 පු	Page 1
							Reference Desig Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	5,460,955	10/24/95	Mosher, et al.	TRADE									
AB	5,547,854	08/20/96	Donahoe et al.										
AC	5,413,778	05/09/95	Kunkel et al.										
		V24	OREIGN PATENT DOCUM	MENTS		47 = 4 = 4 = 4							
		Date	Country	Class	Sub-class	Translation							
	Document No.	Date	Country			(Yes/No)							
AD	94/07542	04/14/94	PCT			<del> </del>							
	0	THER ART (In	cluding Author, Title, Date	, Pertinent Page	es, Etc.)								
AE	1 1 1 00	200 6 11	ls in Molecular Biology, Wile										
	C1 T.D.	1 65 ( 1 1 1	11-6.11.16 (1994). oning and functional expressi	on of two moncy	te chemoattractant p	rotein 1 receptor							
AF	New York 1:22-32, pages 6.11.11-6.11.10 (1994).  Charo, I.F., et al, "Molecular cloning and functional expression of two moncyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails," Proc. Natl. Acad. Sci. U.S.A., 91:2752-2756 (1994).												
AG	Constinue et al. "Minimally modified low density linoprotein induces monocyte chemotacuc protein i maman												
	endothelial cells and smooth muscle cells" (1990) Proc. Natl. Acad. Sci. 87:5134-5138  Edgington, S.M., "Chemokines In Cardiovascular Disease" (1993) Bio/Technology 11:676-681												
AH	Faggiotto, et al. "Studies of Hypercholesterolemia in the Nonhuman Primate -I. Changes that Lead to Fatty Streak												
,AI	$\frac{1}{2}$ $\frac{1}$												
AJ	Furutani, et al., "Cloning and sequencing of the cDNA for human monocyte chemotactic and activating in												
A 77	Gao et al. "Structure and functional expression of the human macrophage inflammatory protein larger to					la/RANTES							
AK	# (1002) The January of Experimental Medicine 1//14/1-14//												
AL	Gearing, David P. et al. "Expression cloning of a receptor for human granulocyte-macrophage colony-standarding												
AM	factor" (1989) 8(12) 3667-3676  Holmes, et al. "Structure and functional expression of a human interleukin-8 receptor" (1991) Science 253:1278-												
AW	Jones et al., "Potential Role of Monocyte Chemoattractant Protein 1/JE inMonocyte/Macrophage-Dependent IgA												
AN	L +	A less slittes in	. +ka Dat" (1997) I ne Iniimai	OI IIIIIIIIIIIIIIIIII	177,617/-610/								
40	Koch et al., "I	Enhanced produc	tion of monocyte chemoattra	ctant protein-1 in	rheumatoid arthritis	" (1992) The							
AO	Town-1 of Clinical Investigation Inc. 00:772-779												
AP	Murphy, P.M. and Tiffany, H.L., "Cloning of complementary DNA encoding a functional human interleukin-8 receptor" (1991) Science 253:1280-1283												
AQ	Nelken et al., "Monocyte chemoattractant protein-1 in human atheromatous plaques" (1991) J. Clin. Invest.												
AR	88:1121-1127  Neote, et al., "Molecular cloning, functional expression, and signaling characteristics of a C-C Chemokine												
	Receptor" (1993) Cell 72:415-425  Oppenheim, et al. "Properties of Genes and Gene Products of the intercrine family" (1991) Annual Review of												
AS	Oppenheim, et al. "Properties of Genes and Gene Products of the interestine family (1994) 1 Immunology 9:620-648												
AT	Reek et al., C	ell 50:667 (1987	)										
AU	Rollins, B.J. and Sunday, M.E., "Suppression of tumor formation in vivo by expression of the JE gene in malignar cells" (1991) Molecular and Cellular Biology 11(6):3125-3131												
AV	Van Riper et al., "Characterization and Species Distribution of High Affinity GTP-coupled Receptors for Human Rantes and Monocyte Chemoattractant Protein 1" (1993) J. Fxp. Med. 177:851-856  Walter, et al. "Macrophage Infiltration and Growth of Sarcoma Clones Expressing Different Amounts of Monocyte Chemoattractant Protein 1" (1993) April 1995 (1995) 19												
		TOTION A TO CHICKING	attiaciant rotalization	1 12pt 1:20 at 1									

FORM PTO-1449 (Modified)		Attorney Docket No.: 02307K-085040US Application No.: 09/625,573				
LIST OF PATENTS AND PUBLICATIONS FOR		Applicant: Israel F. Charo				
APPLICANT'S	INFORMATION DISCLOSURE	Filing Date: July 25, 2000 Group: Unassigned				
STATEMENT (	Use several sheets if necessary)					
AX	Wang, et al., "Identification of RANTES Receptors on Human Monocytic Cells: Competition for Binding and					
	Desensitization by Homologous Chemotactic .Cytokines" (1993) The Journal of Experimental Medicine 177:699-					
	705					
AY	Watson, S. et al., eds. The G-Protein Linked Receptor - Facts Book, London, Academic Press (1994) Introduction,					
	nn 2-6					
AZ	Wolpe, S.D. and Cerami, A., "Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of					
	cytokines" (1989) The FASEB Journal 3:2565-2573					
BA	Yamagami, S. et al, "cDNA cloning and functional expression of a human monocyte chemoattractant protein 1					
	receptor," Biochem. Biophys. Res. Com., volume 202, 2:1156-1162 (July 29, 1994).					
BB	Ylä-Herttuala, et al. "Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and					
	rabbit atherosclerotic lesions" (1991) Proc. Natl. Acad. Sci. 88:5252-5256					
BC ~	Yoshimura, et al. (1990) J. Immunology 145: 292-297					
	Yoshimura, et al., "Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants"					
BD	(1989) The Journal of Experimental Medicine 169:1449-1459					
	<u> </u>	DATE CONSIDERED				
EXAMINER		DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.